酪酸梭菌二联活菌胶囊辅助治疗变应性鼻炎的疗效观察
发布时间：2018-11-20 06:42
【摘要】：目的:通过对比应用酪酸梭菌二联活菌胶囊(又名常乐康)等药物前后变应性鼻炎患者血清中IL-10、TGF-β1及四分法、视觉模拟量表、鼻结膜炎生活质量调查问卷评分的变化来观察常乐康辅助治疗变应性鼻炎的的疗效。方法:1.根据纳入标准、排除标准、退出标准最终收集到符合条件的季节性中-重度变应性鼻炎患者研究组20例,对照组20例。研究组给予常乐康、枸地氯雷他定片、糠酸莫米松鼻喷剂治疗2周后继续给予常乐康维持治疗6周,而停用其他两种药物。对照组给予枸地氯雷他定片+糠酸莫米松鼻喷剂治疗2周后退出临床实验。2.收集研究组和对照组患者在治疗前、治疗2周后、治疗结束后血清并通过四分法、视觉模拟量表、鼻结膜炎生活质量调查问卷(RQLQ)进行评分。同时收集健康成人血清10份作为正常组。最后采用酶联免疫吸附试验检测三组中每位受试者每个阶段血清中IL-10、TGF-β1水平。3.统计数据:(1)研究组患者在治疗前、治疗2周后、治疗结束后IL-10、TGF-β1、症状评分、RQLQ总评分的变化有无统计学意义;(2)研究组和对照组在治疗2周后IL-10、TGF-β1、症状评分、RQLQ总评分有无差别;(3)分析IL-10水平、TGF-β1水平分别与症状评分、RQLQ总评分的相关性。结果:1.治疗前正常组、研究组、对照组血清TGF-β1和IL-10水平总体差异有统计学意义(P0.001),且研究组、对照组均显著低于正常组。2.随着治疗时间的增加,研究组患者血清中IL-10、TGF-β1水平逐渐升高(治疗8周后治疗2周后治疗前),四分法眼部症状评分、VAS眼部症状评分、RQLQ总分逐渐降低(治疗8周后治疗2周后治疗前)。3.对照组患者治疗2周后血清IL-10、TGF-β1均高于治疗前(P0.001),四分法鼻部症状、四分法眼部症状,VAS鼻部症状、VAS眼部症状,RQLQ总评分均低于治疗前(P0.001)。4.治疗2周后研究组患者血清IL-10高于对照组(P0.001),但两组间TGF-β1、症状及生活质量评分均无统计学差异(P0.05)5.治疗前AR患者血清IL-10、TGF-β1与四分法鼻部症状评分、四分法眼部症状评分、VAS鼻部症状评分、VAS眼部症状评分、RQLQ总分之间均无线性相关关系(P0.05)。结论:1.AR患者血清IL-10、TGF-β1水平低于正常组提示IL-10、TGF-β1可能参与了AR的发病。2.酪酸梭菌二联活菌胶囊可能对研究组AR患者血清IL-10、TGF-β1的产生起促进作用。3.枸地氯雷他定和糠酸莫米松鼻喷剂联合治疗可能对AR患者血清IL-10、TGF-β1的产生起促进作用。4.AR患者在枸地氯雷他定和糠酸莫米松鼻喷剂治疗的基础上加用酪酸梭菌二联活菌胶囊可能比常规的二者联合治疗更能促进血清IL-10的产生,但在症状及生活质量方面没有更明显的改善。5.酪酸梭菌二联活菌胶囊可能对AR患者眼部症状、总生活质量的改善有一定的作用。6.AR患者治疗前血清IL-10、TGF-β1水平可能与其症状、生活质量关联性较小,暂不能用血清IL-10、TGF-β1水平的高低来评估AR的病情严重程度。
[Abstract]:Objective: to compare the application of IL-10,TGF- 尾 1 and quaternion in the serum of patients with allergic rhinitis before and after administration of Clostridium caseinate biplex capsule (also known as Changlekang), and to evaluate the visual analogue scale. To observe the efficacy of Changle Kang in the treatment of allergic rhinitis. Methods: 1. According to the inclusion criteria, exclusion criteria and exit criteria, 20 cases of seasonal moderate to severe allergic rhinitis were collected in the study group and 20 cases in the control group. The study group was treated with Changlekang, loratadine citrate and momethasone furoate nasal spray for 6 weeks, while the other two drugs were stopped. The control group was treated with momethasone furoate for 2 weeks and withdrew from the clinical trial. 2. The patients in the study group and the control group were assessed by the four points visual analogue scale and the quality of life questionnaire (RQLQ) before and after 2 weeks of treatment. At the same time, 10 healthy adult serum samples were collected as normal group. Finally, the serum IL-10,TGF- 尾 1 levels in each of the three groups were measured by enzyme linked immunosorbent assay (Elisa). Statistical data: (1) before treatment, 2 weeks after treatment, and after treatment, the changes of IL-10,TGF- 尾 1, symptom score and total RQLQ score were statistically significant. (2) there were differences in IL-10,TGF- 尾 1, symptom score and total RQLQ score between study group and control group 2 weeks after treatment. (3) the correlation between IL-10 level, TGF- 尾 1 level and symptom score and RQLQ total score were analyzed. The result is 1: 1. The levels of serum TGF- 尾 1 and IL-10 in normal group, study group and control group were significantly different before treatment (P0.001), and the levels of serum TGF- 尾 1 and IL-10 in study group and control group were significantly lower than those in normal group. With the increase of treatment time, the serum levels of IL-10,TGF- 尾 1 in the study group increased gradually (8 weeks after treatment and 2 weeks after treatment before treatment), the four-point ocular symptom score, the VAS ocular symptom score, The total score of RQLQ gradually decreased (8 weeks after treatment 2 weeks before treatment). 3. After 2 weeks of treatment, the serum IL-10,TGF- 尾 1 levels in the control group were significantly higher than those before treatment (P0.001). The scores of nasal symptoms, eye symptoms, VAS nasal symptoms, VAS ocular symptoms and RQLQ scores were significantly lower in the control group than before treatment (P0.001). After 2 weeks of treatment, the serum IL-10 of the patients in the study group was higher than that of the control group (P0.001), but there was no significant difference in TGF- 尾 1, symptom and quality of life score between the two groups (P0.05). Before treatment, there was no linear correlation between serum IL-10,TGF- 尾 1 and four score nasal symptom score, four score eye symptom score, VAS nasal symptom score, VAS ocular symptom score and total RQLQ score (P0.05). Conclusion: the level of serum IL-10,TGF- 尾 1 in 1.AR patients is lower than that in normal controls, suggesting that IL-10,TGF- 尾 1 may be involved in the pathogenesis of AR. 2. 2. Clostridium caseate combined with living bacillus capsule may promote the production of serum IL-10,TGF- 尾 1 in AR patients in study group. 3. 3. Combined treatment of citric loratadine and momethasone furoate nasal spray may be used in the treatment of serum IL-10, in patients with AR The effect of TGF- 尾 _ 1 on the production of TGF- 尾 _ 1.The combination of clostridium butyrate and momethasone furoate nasal spray in patients with 4.AR may promote the production of serum IL-10 more than the conventional combination therapy of Clostridium caseate and Clostridium caseate. But there was no more significant improvement in symptoms and quality of life. The capsule of Clostridium caseinate combined with living bacteria may have a certain effect on the improvement of ocular symptoms and total quality of life in patients with AR. The serum IL-10,TGF- 尾 1 level may be related to the symptoms of patients with 6.AR before treatment, and the quality of life is not related to the patients' quality of life. Serum levels of IL-10,TGF- 尾 1 could not be used to assess the severity of AR.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R765.21
本文编号：2344102
[Abstract]:Objective: to compare the application of IL-10,TGF- 尾 1 and quaternion in the serum of patients with allergic rhinitis before and after administration of Clostridium caseinate biplex capsule (also known as Changlekang), and to evaluate the visual analogue scale. To observe the efficacy of Changle Kang in the treatment of allergic rhinitis. Methods: 1. According to the inclusion criteria, exclusion criteria and exit criteria, 20 cases of seasonal moderate to severe allergic rhinitis were collected in the study group and 20 cases in the control group. The study group was treated with Changlekang, loratadine citrate and momethasone furoate nasal spray for 6 weeks, while the other two drugs were stopped. The control group was treated with momethasone furoate for 2 weeks and withdrew from the clinical trial. 2. The patients in the study group and the control group were assessed by the four points visual analogue scale and the quality of life questionnaire (RQLQ) before and after 2 weeks of treatment. At the same time, 10 healthy adult serum samples were collected as normal group. Finally, the serum IL-10,TGF- 尾 1 levels in each of the three groups were measured by enzyme linked immunosorbent assay (Elisa). Statistical data: (1) before treatment, 2 weeks after treatment, and after treatment, the changes of IL-10,TGF- 尾 1, symptom score and total RQLQ score were statistically significant. (2) there were differences in IL-10,TGF- 尾 1, symptom score and total RQLQ score between study group and control group 2 weeks after treatment. (3) the correlation between IL-10 level, TGF- 尾 1 level and symptom score and RQLQ total score were analyzed. The result is 1: 1. The levels of serum TGF- 尾 1 and IL-10 in normal group, study group and control group were significantly different before treatment (P0.001), and the levels of serum TGF- 尾 1 and IL-10 in study group and control group were significantly lower than those in normal group. With the increase of treatment time, the serum levels of IL-10,TGF- 尾 1 in the study group increased gradually (8 weeks after treatment and 2 weeks after treatment before treatment), the four-point ocular symptom score, the VAS ocular symptom score, The total score of RQLQ gradually decreased (8 weeks after treatment 2 weeks before treatment). 3. After 2 weeks of treatment, the serum IL-10,TGF- 尾 1 levels in the control group were significantly higher than those before treatment (P0.001). The scores of nasal symptoms, eye symptoms, VAS nasal symptoms, VAS ocular symptoms and RQLQ scores were significantly lower in the control group than before treatment (P0.001). After 2 weeks of treatment, the serum IL-10 of the patients in the study group was higher than that of the control group (P0.001), but there was no significant difference in TGF- 尾 1, symptom and quality of life score between the two groups (P0.05). Before treatment, there was no linear correlation between serum IL-10,TGF- 尾 1 and four score nasal symptom score, four score eye symptom score, VAS nasal symptom score, VAS ocular symptom score and total RQLQ score (P0.05). Conclusion: the level of serum IL-10,TGF- 尾 1 in 1.AR patients is lower than that in normal controls, suggesting that IL-10,TGF- 尾 1 may be involved in the pathogenesis of AR. 2. 2. Clostridium caseate combined with living bacillus capsule may promote the production of serum IL-10,TGF- 尾 1 in AR patients in study group. 3. 3. Combined treatment of citric loratadine and momethasone furoate nasal spray may be used in the treatment of serum IL-10, in patients with AR The effect of TGF- 尾 _ 1 on the production of TGF- 尾 _ 1.The combination of clostridium butyrate and momethasone furoate nasal spray in patients with 4.AR may promote the production of serum IL-10 more than the conventional combination therapy of Clostridium caseate and Clostridium caseate. But there was no more significant improvement in symptoms and quality of life. The capsule of Clostridium caseinate combined with living bacteria may have a certain effect on the improvement of ocular symptoms and total quality of life in patients with AR. The serum IL-10,TGF- 尾 1 level may be related to the symptoms of patients with 6.AR before treatment, and the quality of life is not related to the patients' quality of life. Serum levels of IL-10,TGF- 尾 1 could not be used to assess the severity of AR.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R765.21
【参考文献】
相关期刊论文 前6条
1 乔燕;刘涛;;益生菌对变应性疾病作用机制的研究进展[J];临床耳鼻咽喉头颈外科杂志;2016年18期
2 车娟;赵洪春;李金玲;王延飞;;变应性鼻炎患者血清IL-33和可溶性ST_2检测的临床意义[J];现代免疫学;2016年01期
3 卢汉桂;邱前辉;卢川;陈少华;韩虹;;变应性鼻炎患者特异性免疫治疗前后TGF-β、IL-10和IL-17的变化及和症状关系的研究[J];临床耳鼻咽喉头颈外科杂志;2012年02期
4 熊祖明;袁杰利;;酪酸梭菌的研究与应用进展[J];中国微生态学杂志;2011年12期
5 张克军;王长生;成娜莎;王宁;刘太琴;王斌全;;太原市30年间2次气传花粉调查结果对比[J];中华临床免疫和变态反应杂志;2011年02期
6 Man-Chin Hua;Tzou-Yien Lin;Chien-Chang Chen;;Probiotic Bio-Three induces Th1 and anti-inflammatory effects in PBMC and dendritic cells[J];World Journal of Gastroenterology;2010年28期
，本文编号：2344102
本文链接：https://www.wllwen.com/yixuelunwen/wuguanyixuelunwen/2344102.html
最近更新
教材专著
